Results 31 to 40 of about 42,703 (308)
Indian Journal of Rheumatology, 2017 Rheumatoid arthritis (RA) is a chronic, disabling inflammatory arthritis often treated with a variety of disease-modifying antirheumatic drugs (DMARDs), whether conventional synthetic DMARDs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), or biological
Abhishek Zanwar +6 more
doaj +1 more source
JMIR Serious Games, 2022 BackgroundPatients’ implicit attitudes toward medication need and concerns may influence their adherence. Targeting these implicit attitudes by combining game-entertainment with medication-related triggers might improve medication
Bart PH Pouls +4 more
doaj +1 more source
Mode of Action of Antirheumatic Drugs [PDF]
BMJ, 1971 The concentrations of free and protein-bound L-tryptophan were measured in sera from normal subjects, patients with rheumatoid arthritis, pregnant women, and patients with jaundice. In the patients with rheumatoid arthritis receiving treatment with one or more antirheumatic drugs the percentage of the amino-acid bound to the circulating proteins was ...
P. D. Dawkins +3 more
openaire +3 more sources
Frontiers in Pharmacology, 2020 Mesenchymal stem cell (MSC)–based articular regeneration might be beneficial for both protecting and rebuilding cartilaginous tissues in the management of rheumatoid arthritis. However, it is unclear how current immunosuppressive strategies influence the
Shuang Liu +3 more
doaj +1 more source
Treatment of juvenile rheumatoid arthritis [PDF]
Korean Journal of Pediatrics, 2010 The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be ...
Kwang Nam Kim
doaj +1 more source
Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. [PDF]
, 2009 ObjectiveC-reactive protein (CRP) levels>3 mg/L and>10 mg/L are associated with high and very high cardiovascular risk, respectively, in the general population.
Graf, Jonathan +3 more
core +4 more sources
Arthritis Research & Therapy, 2022 Background There is limited information regarding disease-modifying antirheumatic drug (DMARD)-dependent risks of overall, incident, and recurrent herpes zoster (HZ) during first-line biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD ...
Seogsong Jeong +5 more
doaj +1 more source
Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]
, 2019 Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro +5 more
core +3 more sources
Therapeutic Advances in Musculoskeletal Disease, 2021 Objective: To evaluate the comparative efficacy and safety of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to at least one disease ...
Chenghua Weng +5 more
doaj +1 more source
Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
Pharmaceuticals, 2021 Coronavirus disease 2019 (COVID-19) remains a global threat to humanity. Its pathogenesis and different phases of disease progression are being elucidated under the pandemic.
Mai Kawazoe +2 more
doaj +1 more source